Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Mydecine finishes harvest and is preparing to export 20 kgs of psilocybin mushrooms from Jamaica to Canada for increased international supply scale of cGMP nature-sourced psilocybin

Denver, Colorado, U.S.A., December 8, 2020– Mydecine Innovations Group ™ (CSE: MYCO)( OTC: MYCOF)(” Mydecine” or the “Business’), an emerging biopharma and life sciences business devoted to the research study, advancement, and approval of alternative nature-sourced restorative medication for mainstream usage, revealed that it has actually finished its very first business harvest of 20 kgs of psilocybin mushrooms at its research study and growing center in Jamaica. The Business is now preparing to export the harvest to its Canadian cGMP Center which has a Health Canada schedule 1 Dealership’s License connected to it, enabling legal import.

” We are happy to reveal the conclusion of our very first business harvest of natural psilocybin mushrooms,” stated Joshua Bartch, CEO and Chairman of Mydecine. “There is more research study required on these substances in order to much better comprehend the entourage impact experienced by clients which has actually revealed considerably efficient outcomes compared to single-molecule artificial psilocybin in initial research studies. As the market grows, the requirement for naturally taking place psilocybin and access to big amounts of these particles will be vital and we are delighted to be the very first to advance this motion at scale.”

As soon as gotten by the Business’s center in Canada, the psilocybin mushrooms will be drawn out, improved and developed into a cGMP end product for regulated restorative functions. Mydecine’s end product be provided for purchase by other certified organizations and business carrying out medical research study into the effectiveness of these substances to deal with different health conditions consisting of stress and anxiety, dependency, anxiety and PTSD. Parts of the harvest will likewise be utilized for Mydecine’s exclusive hereditary, pharmacology, and medical research study. The medical usage will be for the research studies and establishing procedures of psilocybin-assisted psychiatric therapy to deal with PTSD in veterans and other frontline employees.

About Mydecine Innovations Group

Mydecine Innovations Group ™ ( CSE: MYCO)( OTC: MYCOF) is a life sciences business committed to establishing and advertising ingenious services for dealing with psychological illness and improving wellness. The business’s world-renowned medical and clinical board of advisers is advancing a robust R&D pipeline of psychedelic obtained rehabs, unique substances, treatments, and managed drug shipment systems. Mydecine has unique access to a complete cGMP accredited pharmaceutical production center with the capability to import/export, extract, and evaluate natural and artificial psychedelic substances with complete federal government approval through Health Canada.

For additional info about Mydecine Innovations Group, Inc., please check out the Business’s profile on SEDAR at or check out the Business’s site at

The Canadian Securities Exchange has actually neither authorized nor disapproved the contents of this press release and accepts no duty for the adequacy or precision hereof. This press release includes positive declarations, which connect to future occasions or future efficiency and show management’s present expectations and presumptions. Such positive declarations show management’s present beliefs and are based upon presumptions made by and info presently readily available to the Business. Readers are warned that these positive declarations are neither pledges nor assurances, and go through threats and unpredictabilities that might trigger future outcomes to vary materially from those anticipated consisting of, without restriction, the schedule and connection of funding, the capability of the Business to sufficiently secure and implement its copyright, the Business’s capability to bring its items to business production, continued development of the international adaptive path medication, natural health items and digital health markets, and the threats provided by the extremely managed and competitive market worrying the advancement, production, sale and usage of the Business’s items. Although the Business has actually tried to recognize essential aspects that might trigger real outcomes to vary materially from those included in positive info, there might be other aspects that trigger results not to be as expected, approximated or planned. There can be no guarantee that such info will show to be precise, as real outcomes and future occasions might vary materially from those expected in such info. These positive declarations are made since the date hereof and the Business does not presume any commitment to upgrade or modify them to show brand-new occasions or scenarios conserve as needed under suitable securities legislation. This press release does not make up a deal to offer securities and the Business is not getting a deal to purchase securities in any jurisdiction in which such deal, solicitation or sale would be illegal previous to registration or credentials under the securities laws of such jurisdiction. This press release does not make up a deal of securities for sale in the United States. These securities have not and will not be signed up under United States Securities Act of 1933, as changed, or any state securities laws and might not be used or offered in the United States or to a U.S. Individual unless so signed up, or an exemption from registration is trusted.

P lease See Disclaimer

Latest posts